Chronic use of statins and acetylsalicylic acid and incidence of post-endoscopic retrograde cholangiopancreatography acute pancreatitis: A multicenter, prospective, cohort study.
endoscopic retrograde cholangiopancreatography
hydroxymethylglutaryl-CoA reductase inhibitors
pancreatitis
prevention
salicylates
Journal
Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society
ISSN: 1443-1661
Titre abrégé: Dig Endosc
Pays: Australia
ID NLM: 9101419
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
received:
07
04
2020
accepted:
20
07
2020
pubmed:
28
7
2020
medline:
29
7
2021
entrez:
27
7
2020
Statut:
ppublish
Résumé
Post-endoscopic retrograde cholangiopancreatography (ERCP) acute pancreatitis (PEP) is a frequent complication of this endoscopic procedure. Chronic statin intake has been linked to lower incidence and severity of acute pancreatitis (AP). Periprocedural rectal administration of non-steroidal anti-inflammatory drugs is protective against PEP, but the role of chronic acetylsalicylic acid (ASA) treatment is unclear. We aimed to investigate whether statins and chronic ASA intake are associated with lower risk of PEP. An international, multicenter, prospective cohort study. Consecutive patients undergoing ERCP in seven European centers were included. Patients were followed-up to detect those with PEP. Multivariate analysis by means of binary logistic regression was performed, and adjusted odds ratios (aORs) were calculated. A total of 1150 patients were included, and 70 (6.1%) patients developed PEP. Among statins users, 8.1% developed PEP vs. 5.4% among non-users (P = 0.09). Multivariate analysis showed no association between statin use and PEP incidence (aOR 1.68 (95% CI 0.94-2.99, P = 0.08)). Statin use had no effect on severity of PEP, being mild in 92.0% of statin users vs. 82.2% in non-statin users (P = 0.31). Chronic ASA use was not associated with PEP either (aOR 1.02 (95% CI 0.49-2.13), P = 0.96). Abuse of alcohol and previous endoscopic biliary sphincterotomy were protective factors against PEP, while >1 pancreatic guidewire passage, normal bilirubin values, and duration of the procedure >20 minutes, were risk factors. The use of statins or ASA is not associated with a lower risk or a milder course of PEP.
Substances chimiques
Hydroxymethylglutaryl-CoA Reductase Inhibitors
0
Aspirin
R16CO5Y76E
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
639-647Subventions
Organisme : Acibadem University and Karolinska Institute
Informations de copyright
© 2020 Japan Gastroenterological Endoscopy Society.
Références
Peery AF, Crockett SD, Murphy CC et al. Burden and cost of gastrointestinal, liver, and pancreatic diseases in the United States: update 2018. Gastroenterology 2019; 156: 254-72.
Dumonceau JM, Andriulli A, Elmunzer BJ et al. Prophylaxis of post-ERCP pancreatitis: European society of gastrointestinal endoscopy (ESGE) guideline - updated June 2014. Endoscopy 2014; 46: 799-815.
Elmunzer BJ, Scheiman JM, Lehman GA et al. A randomized trial of rectal indomethacin to prevent post-ERCP pancreatitis. N Engl J Med 2012; 366: 1414-22.
Andriulli A, Loperfido S, Napolitano G et al. Incidence rates of post-ERCP complications: a systematic survey of prospective studies. Am J Gastroenterol 2007; 102: 1781-8.
Sahar N, Ross A, Lakhtakia S et al. Reducing the risk of post-endoscopic retrograde cholangiopancreatography pancreatitis using 4-Fr pancreatic plastic stents placed with common-type guidewires: results from a prospective multinational registry. Dig Endosc. 2019; 31: 299-306.
Lyu Y, Cheng Y, Wang B, Xu Y, Du W. What is impact of nonsteroidal anti-inflammatory drugs in the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a meta-analysis of randomized controlled trials. BMC Gastroenterol 2018; 18: 106.
Levenick JM, Gordon SR, Fadden LL et al. Rectal indomethacin does not prevent post-ERCP pancreatitis in consecutive patients. Gastroenterology 2016; 150: 911-9.
Bu DX, Griffin G, Lichtman AH. Mechanisms for the anti-inflammatory effects of statins. Curr Opin Lipidol 2011; 22: 165-70.
de-Madaria E Statins for the prevention of acute pancreatitis. Am J Gastroenterol 2017; 112: 1765-7.
Etienne D, Reda Y. Statins and their role in acute pancreatitis: case report and literature review. World J Gastrointest Pharmacol Ther 2014; 5: 191-5.
Poropat G, Archibugi L, Korpela T, Cardenas-Jaen K, de Madaria E, Capurso G. Statin use is not associated with an increased risk of acute pancreatitis. A meta-analysis of observational studies. United European Gastroenterol J 2018; 6: 1206-14.
Preiss D, Tikkanen MJ, Welsh P et al. Lipid-modifying therapies and risk of pancreatitis: a meta-analysis. JAMA 2012; 308: 804-11.
Wu BU, Pandol SJ, Liu IL. Simvastatin is associated with reduced risk of acute pancreatitis: findings from a regional integrated healthcare system. Gut 2015; 64: 133-8.
Gornik I, Gasparovic V, Gubarev Vrdoljak N, Haxiu A, Vucelic B. Prior statin therapy is associated with milder course and better outcome in acute pancreatitis-a cohort study. Pancreatology 2013; 13: 196-200.
Mahamid M, Watad A, Bragazzi NL et al. Chronic use of statins and their effect on prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis. Front Pharmacol 2018; 9: 704.
Facciorusso A, Buccino VR, Prete VD, Antonino M, Contaldo A, Muscatiello N. Statins decrease the risk of acute pancreatitis after endoscopic ultrasound fine-needle aspiration of pancreatic cysts. Hepatobiliary Pancreat Dis Int 2020; 19: 74-9.
Korpela T, Cardenas-Jaen K, Archibugi L et al. Chronic use of statins and risk of post-ERCP acute pancreatitis (STARK): study protocol for an international multicenter prospective cohort study. Dig Liver Dis. 2018; 50: 1362-5.
von Elm E, Altman DG, Egger M et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007; 370: 1453-7.
Banks PA, Bollen TL, Dervenis C et al. Classification of acute pancreatitis-2012: revision of the Atlanta classification and definitions by international consensus. Gut 2013; 62: 102-11.
Cotton PB, Lehman G, Vennes J et al. Endoscopic sphincterotomy complications and their management: an attempt at consensus. Gastrointest Endosc 1991; 37: 383-93.
Martinez-Moneo E, Cardenas-Jaen K, Fernandez-Laso AB et al. Statin consumption and risk of post-endoscopic retrograde cholangiopancreatography pancreatitis. PancreatologyPublished online: 7 May 2020; https://doi.org/10.1016/j.pan.2020.05.002
Dumonceau JM, Kapral C, Aabakken L et al. ERCP-related adverse events: European society of gastrointestinal endoscopy (ESGE) guideline. Endoscopy 2020; 52: 127-49.
Hakuta R, Nakai Y, Hamada T et al. Regular statin use and incidence of postendoscopic retrograde cholangiopancreatography pancreatitis. J Clin GastroenterolPublished online: 30 Dec 2019; https://doi.org/10.1097/MCG.0000000000001312
Weiss FU, Laemmerhirt F, Lerch MM. Etiology and risk factors of acute and chronic pancreatitis. Visc Med 2019; 35: 73-81.
Kleeff J, Whitcomb DC, Shimosegawa T et al. Chronic pancreatitis.Nat Rev Dis Primers 2017; 3: 17060.
Hookey LC, RioTinto R, Delhaye M, Baize M, Le Moine O, Deviere J. Risk factors for pancreatitis after pancreatic sphincterotomy: a review of 572 cases. Endoscopy 2006; 38: 670-6.
Freeman ML, DiSario JA, Nelson DB et al. Risk factors for post-ERCP pancreatitis: a prospective, multicenter study. Gastrointest Endosc 2001; 54: 425-34.
Debenedet AT, Raghunathan TE, Wing JJ, Wamsteker EJ, DiMagno MJ. Alcohol use and cigarette smoking as risk factors for post-endoscopic retrograde cholangiopancreatography pancreatitis. Clin Gastroenterol Hepatol 2009; 7: 353-8e4.
Testoni PA, Mariani A, Giussani A et al. Risk factors for post-ERCP pancreatitis in high- and low-volume centers and among expert and non-expert operators: a prospective multicenter study. Am J Gastroenterol 2010; 105: 1753-61.
Funatsu E, Masuda A, Takenaka M et al. History of post-endoscopic retrograde cholangiopancreatography pancreatitis and acute pancreatitis as risk factors for post-ERCP pancreatitis. Kobe J Med Sci 2017; 63: E1-E8.
Meister T, Heinzow H, Heinecke A, Hoehr R, Domschke W, Domagk D. Post-ERCP pancreatitis in 2364 ERCP procedures: is intraductal ultrasonography another risk factor? Endoscopy 2011; 43: 331-6.